The latest treatments for peripheral artery disease (PAD) combine newer medications that reduce limb complications, minimally invasive procedures that crack open calcified arteries, and dissolving scaffolds that hold vessels open and then disappear. The 2024 guidelines from the American College of Cardiology and American Heart Association represent the most comprehensive update in years, reflecting a shift toward more aggressive blood-flow preservation and structured exercise programs alongside these newer technologies.
Dual Pathway Blood Thinning
One of the most significant pharmacological advances is combining a low-dose blood thinner with aspirin rather than using aspirin alone. In the COMPASS trial of 7,470 patients with stable PAD, adding low-dose rivaroxaban to aspirin reduced major cardiovascular events by 28% and cut major adverse limb events, including amputation and severe blockages requiring emergency intervention, by 46%. This “dual pathway inhibition” strategy works by targeting two different steps in the clotting process simultaneously.
The tradeoff is a modest increase in bleeding risk, so this combination isn’t appropriate for everyone. It’s most commonly considered for people with PAD who are at high risk for limb loss or cardiovascular events but don’t have a high bleeding risk.
Intravascular Lithotripsy for Calcified Arteries
Heavily calcified arteries have long been one of the toughest challenges in PAD treatment. Standard balloon angioplasty struggles to expand a vessel packed with calcium deposits. Intravascular lithotripsy (IVL) uses the same concept as kidney stone treatment: targeted shockwaves that crack calcium from inside the artery, making it pliable enough to open fully.
Results from the Disrupt PAD III trial showed IVL significantly outperformed standard balloon angioplasty in calcified thigh and upper knee arteries. At one year, 80.5% of IVL-treated vessels remained open compared to 68% with balloon angioplasty alone. At two years, the gap widened further: 74.4% versus 57.7%. Perhaps most notably, only 4.6% of IVL patients needed a bailout stent during the procedure compared to 18.3% with standard balloons. Avoiding stents matters because it preserves future treatment options if the disease progresses.
Dissolving Scaffolds for Below-the-Knee Disease
Arteries below the knee are small, and permanent metal stents placed there tend to fracture or trigger re-narrowing. A newer approach uses drug-eluting resorbable scaffolds that prop the artery open, release medication to prevent scar tissue, and then gradually dissolve.
Two-year results from the LIFE-BTK trial showed the Esprit BTK scaffold maintained artery patency in 68.8% of patients compared to 45.4% with balloon angioplasty alone. Re-narrowing occurred in only 28.5% of scaffold patients versus 48.2% with balloons, and the need for repeat procedures dropped roughly in half (9.7% versus 18.6%). Because the scaffold eventually absorbs, the artery regains its natural flexibility, and doctors retain the option to treat that segment again if needed.
Drug-Coated Balloons and Safety Concerns Resolved
Drug-coated balloons deliver medication directly to the artery wall during angioplasty, reducing the chance of re-narrowing without leaving a permanent implant behind. These devices use paclitaxel, a drug that inhibits cell growth. A 2018 analysis raised concerns about a possible late mortality signal with paclitaxel-coated devices, which led to a period of caution and reduced use.
The FDA has since reviewed extensive additional data, including updated meta-analyses with longer follow-up (up to five years), the large SWEDEPAD trial, the VOYAGER PAD study, U.S. Veterans Health Administration data, and a Medicare safety study. None found an increased mortality risk. The FDA concluded that the data does not support an excess mortality risk for paclitaxel-coated devices, effectively clearing these tools for continued use. This is significant because drug-coated balloons remain one of the most effective options for treating blockages in the thigh arteries.
Dissection Repair Without Traditional Stents
When a balloon is inflated inside an artery, it sometimes causes a dissection, a small tear in the vessel wall that can limit blood flow. Traditionally, a full-length stent would be placed to tack down the flap. The Tack Endovascular System offers a more targeted fix: tiny implants that pin down only the torn section, covering far less of the artery than a conventional stent.
In clinical testing, the device deployed successfully in 95.8% of patients, and 99.5% of procedures achieved vessel patency without needing a bailout stent. At 12 months, primary patency in treated arteries was 65.6%. The key advantage is metal coverage reduction. Less metal in the artery means less chronic irritation and more flexibility for future treatments.
Diabetes Medications That Protect Limbs
For the roughly half of PAD patients who also have type 2 diabetes, a class of diabetes drugs originally designed to lower blood sugar has shown unexpected benefits for limb preservation. SGLT2 inhibitors (such as dapagliflozin and empagliflozin) appear to significantly reduce adverse limb events in people with both conditions.
In a national cohort study comparing SGLT2 inhibitors to another common diabetes drug class, SGLT2 inhibitor use was associated with a 57% lower rate of limb amputation (0.54 versus 1.23 per 100 person-years) and a 27% lower rate of limb ischemia requiring a revascularization procedure. These drugs also lowered the risk of heart failure by 34% and cardiovascular death by 33% in this population. These benefits appear to extend beyond blood sugar control, likely involving improvements in blood vessel health and inflammation.
Supervised Exercise as a Covered Treatment
Structured walking programs remain one of the most effective treatments for PAD-related leg pain, and they’re now a reimbursable medical treatment rather than just general advice. Medicare covers up to 36 supervised exercise sessions over 12 weeks, with each session lasting 30 to 60 minutes. If you’re improving, an additional 36 sessions can be approved with a second referral from your doctor.
These aren’t casual walks. Supervised exercise therapy for PAD typically involves treadmill walking to the point of moderate leg discomfort, resting until it subsides, and repeating. Over weeks, this process stimulates your body to grow small collateral blood vessels around the blockages, effectively building natural bypasses. The 2024 guidelines emphasize supervised exercise as a first-line treatment for people with claudication, the cramping leg pain that comes with walking.
How Severity Guides Treatment Choices
PAD exists on a spectrum, and the latest approach to treatment starts with precise staging. The ankle-brachial index (ABI), a painless test comparing blood pressure in your ankle to your arm, provides the initial picture. Normal values fall between 1.00 and 1.40. Values of 0.91 to 0.99 are borderline, 0.41 to 0.90 indicate mild to moderate disease, and anything at or below 0.40 signals severe PAD.
For people facing possible limb loss, doctors now use the WIfI classification system, which scores three factors on a 0-to-3 scale: wound severity (from no ulcer to extensive tissue loss), ischemia (how blood-starved the limb is), and foot infection (from none to systemic). This combined score predicts amputation risk and helps determine whether revascularization, wound care, or both are needed. A high ischemia score with a low wound score, for instance, points toward restoring blood flow as the priority, while a high infection score may mean treating the infection before any procedure.
The 2024 guidelines organize treatment recommendations across four distinct stages: asymptomatic disease, chronic symptoms like claudication, chronic limb-threatening ischemia, and acute limb ischemia. Each stage has its own treatment ladder, starting with medical management and exercise for early disease and moving toward revascularization procedures for advanced cases. The overall direction is toward intervening earlier with medications and exercise to prevent progression, reserving the newer procedural technologies for disease that doesn’t respond to conservative measures or has already reached a critical stage.